Evaxion Biotech A/S (EVAX) Stock

About Evaxion Biotech A/S

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

Evaxion Biotech A/S is headquartered in DK.

Evaxion Biotech A/S (EVAX) stock trades at $3.05 with a market capitalization of $19.27M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.99, reflecting a net loss over the last twelve months, price-to-book of 1.93, price-to-sales of 2.56. Over the past 52 weeks the stock has ranged between $2.45 and $12.15, and currently trades 74.9% below its 52-week high.

On profitability, Evaxion Biotech A/S generates a return on equity (ROE) of -73.56% (negative, reflecting a net loss), return on capital employed of -38.87%, an operating margin of -122.05%, a net profit margin of -129.63%.

Official website: www.evaxion-biotech.com

Evaxion Biotech A/S by the numbers, 2017–2025

Compounded, revenue has grown —% a year over five years, —% over three, 166.7% over the last twelve months. Net profit was $-8.0M in 2025.

The most recent net margin is -129.63%. On a trailing twelve-month basis to Mar '26, revenue is $7.0M and net profit $-10.0M.

Borrowings stand at $8.0M, cash on hand is $18.4M, cash from operations was $-7.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged 115.5% over five years, and was -47.1% in the most recent year.

The share price itself has compounded at -59.5% a year over five years, -63.6% over three, 20.1% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Evaxion Biotech A/S (EVAX) — frequently asked questions